StockWatch
·

Ennature Bio Pharma Ltd Q2 FY27 Results

ENNATUREQ2 FY27 Results
Filing
Result:Good· Market: Up#Turnaround#Cost led#Margin expansion
MetricValue (₹ Cr)
Revenue78.46
Total Income78.46
Expenditure71.85
PBT6.61
Net Profit4.89
OPM13.18%
NPM6.23%
EPS2.19
View full financials

Revenue grew a strong 44.9% YoY with a clean loss-to-profit turnaround and margin expansion, but the swing is cost-led (raw material cost cut) rather than volume-driven — revenue actually fell 13% QoQ and the YoY base was a loss-making quarter, so it's healthy but not a standout.

Q2 FY-2027 RESULTS · ENNATURE

Ennature Bio Pharma posts ₹4.89 Cr PAT in debut quarter, reverses year-ago loss

revenue +44.92% · margins expanding

12 Nov 2026 · 3 min read
Revenue

₹78.46 Cr

+44.92% YoY

PAT (standalone)

₹4.89 Cr

Net margin

6.23%

EPS

₹2.19

Ennature Bio Pharma, reporting its first results since listing on NSE and BSE on November 4, 2026, posted standalone revenue from operations of ₹78.46 Cr for Q2 FY27, up 44.9% YoY from a restated ₹54.14 Cr in Q2 FY26, though down 13.2% sequentially from ₹90.39 Cr in Q1 FY27. PAT came in at ₹4.89 Cr — a clean YoY turnaround from a ₹1.28 Cr net loss a year earlier — and up 4.9% QoQ from ₹4.66 Cr in Q1 FY27. There are no brokerage previews or consensus estimates available for this stock, which has been listed for barely over a week, so the print cannot be benchmarked against the street; vsStreet is unknown. Management has placed no formal guidance or outlook on record either, so vsGuidance is also unknown at this stage.

The scoreboard

Q2 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹78.46 Cr——
Expenses₹71.85 Cr——
PAT₹4.89 Cr+4.88%—
Net margin6.23%——
EPS₹2.19——

No year-ago quarter on record — YoY cells may be blank.

Net profit margin expanded sharply to 6.23% from -2.37% in the loss-making year-ago quarter and from 5.15% in Q1 FY27. EBITDA margin (reported as Profit Before Interest, Depreciation and Tax) rose to 13.18% from 11.15% YoY and 11.04% QoQ, even as revenue fell sequentially — pointing to cost discipline rather than volume-driven operating leverage. Cost of materials consumed fell to ₹31.09 Cr (39.6% of revenue) from ₹60.79 Cr (67.2% of revenue) in Q1 FY27, the single biggest driver of the margin step-up. There were no exceptional items in the quarter (unlike the ₹0.28 Cr exceptional item in FY26 full-year), so the swing to profit is on a like-for-like operating basis, not a one-off.

Beyond the headline

What the summary numbers don't show

EPS ₹2.19 (not annualised) vs ₹2.09 in Q1 FY27 and -₹0.57 in Q2 FY26

Comparative-period figures are restated/unaudited, sourced from India Glycols' Biopharma-undertaking books — not reviewed by current statutory auditors

These are Ennature's first results as an independently listed company following the NCLT-approved demerger of the Biopharma undertaking from India Glycols Limited — effective September 1, 2026 with an April 1, 2026 appointed date — and its subsequent listing on NSE and BSE on November 4, 2026, per our event records. The trading-window closure around the November 12 board meeting and the listing itself are the only corporate developments on record this quarter; neither has a direct numeric read-through beyond context. No management press release or earnings commentary has been captured for this filing, so there is no management framing to reconcile against the numbers.

  • W1

    Sequential revenue trend: Q2 FY27 fell 13.2% QoQ to ₹78.46 Cr from ₹90.39 Cr in Q1 FY27 — watch whether Q3 FY27 reverses or confirms a slowdown

  • W2

    Margin sustainability: EBITDA margin jumped to 13.18% this quarter from ~11% in the prior two quarters — confirm whether this is a new run-rate or quarter-specific

  • W3

    No management guidance or concall on record yet for this newly listed entity — first forward-looking commentary from management will be a key marker

Filing has only a standalone statement (single entity, single segment, no subsidiaries). Comparative figures for Q1 FY27, Q2 FY26 and FY26 are restated numbers extracted from India Glycols Ltd's Biopharma-undertaking books per the NCLT-approved demerger (effective 1-Sep-2026) and have NOT been independently audited/reviewed by the company's statutory auditors — only the current quarter carries a limited-review opinion. Minor OCR inconsistency in the year-ago PBT line (661.15 vs printed 136.00/136.04 variants) does not affect the current-period column used here.

Informational and educational content only. Not investment advice.